- Home
- ABTS vs CERO Comparison
ABTS vs CERO Comparison
Compare ABTS & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABTS
- CERO
- Stock Information
- Founded
- ABTS 2010
- CERO 2017
- Country
- ABTS Hong Kong
- CERO United States
- Employees
- ABTS N/A
- CERO N/A
- Industry
- ABTS Computer Software: Programming Data Processing
- CERO
- Sector
- ABTS Technology
- CERO
- Exchange
- ABTS Nasdaq
- CERO Nasdaq
- Market Cap
- ABTS 8.9M
- CERO 9.6M
- IPO Year
- ABTS N/A
- CERO N/A
- Fundamental
- Price
- ABTS $3.48
- CERO $5.92
- Analyst Decision
- ABTS
- CERO Strong Buy
- Analyst Count
- ABTS 0
- CERO 2
- Target Price
- ABTS N/A
- CERO $45.00
- AVG Volume (30 Days)
- ABTS 8.7K
- CERO 258.5K
- Earning Date
- ABTS 08-13-2025
- CERO 08-22-2025
- Dividend Yield
- ABTS N/A
- CERO N/A
- EPS Growth
- ABTS N/A
- CERO N/A
- EPS
- ABTS N/A
- CERO N/A
- Revenue
- ABTS $7,037,156.00
- CERO N/A
- Revenue This Year
- ABTS N/A
- CERO N/A
- Revenue Next Year
- ABTS N/A
- CERO N/A
- P/E Ratio
- ABTS N/A
- CERO N/A
- Revenue Growth
- ABTS 31.69
- CERO N/A
- 52 Week Low
- ABTS $1.35
- CERO $5.41
- 52 Week High
- ABTS $14.10
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- ABTS 38.61
- CERO 26.39
- Support Level
- ABTS $3.40
- CERO $8.07
- Resistance Level
- ABTS $3.89
- CERO $7.60
- Average True Range (ATR)
- ABTS 0.25
- CERO 0.48
- MACD
- ABTS -0.03
- CERO -0.17
- Stochastic Oscillator
- ABTS 9.54
- CERO 14.74
About ABTS Abits Group Inc
Abits Group Inc is a digital data center operator with bitcoin self-mining operations. The group has its subsidiaries in USA, China, Canada and Hong Kong.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.